Invega LAI Injection Timing After 30-Day Interval
For patients on Invega Sustenna (paliperidone palmitate) monthly maintenance dosing, the injection can be given up to 7 days before or after the scheduled 30-day (monthly) time point without clinically significant impact on plasma concentrations 1.
Practical Dosing Window
After the initial two-dose loading regimen, monthly maintenance injections follow this schedule:
- Target: Every 30 days (monthly)
- Acceptable window: ±7 days from the scheduled date
- Earliest administration: 23 days after the previous injection
- Latest administration: 37 days after the previous injection
This means if a patient is due for their injection on day 30, you can safely administer it anytime between day 23 and day 37 without requiring dose adjustments or supplemental oral medication 1.
Management When the Window is Exceeded
If the injection is delayed beyond the 7-day window, management depends on how long it has been since the last dose 1:
4 to 6 weeks since last injection:
- Resume regular monthly dosing immediately at the patient's previously stabilized dose
- Continue monthly intervals thereafter
- No loading doses needed
More than 6 weeks to 6 months since last injection:
- Administer a deltoid injection as soon as possible at the previously stabilized dose (unless it was 234 mg—then use 156 mg)
- Give a second deltoid injection 1 week later at the same dose
- Resume the previously stabilized maintenance dose 1 month after the second injection
More than 6 months since last injection:
- Restart with full initiation regimen: 234 mg deltoid on day 1, then 156 mg deltoid on day 8
- Resume previously stabilized maintenance dose 1 month after the second injection
Clinical Implications
The ±7 day flexibility is particularly valuable in real-world practice for accommodating patient schedules, clinic availability, or logistical challenges without compromising therapeutic plasma concentrations 2, 3. This dosing window was established through population pharmacokinetic modeling demonstrating that these timing variations do not produce clinically significant fluctuations in drug levels 2.
The key pitfall to avoid is allowing doses to drift beyond 6 weeks, as this triggers the need for re-initiation protocols rather than simple continuation of maintenance dosing 1. Implementing proactive reminder systems (phone calls, texts) and involving family/caregivers can help maintain adherence within the acceptable dosing window 4.